Search - tctmd.com

Displaying 121 - 140 of 245

Sort: Relevancy | Date

Presentation THT 2023

Cardiogenic Shock With MCS and Review of Shock Algorithm

Presenter: Raymond Yau

March 21, 2023

Presentation THT 2023

Aortic Stenosis TAVR With Annular Rupture/ Tamponade

Presenter: Thomas Waggoner

March 21, 2023

Presentation THT 2023

Cardiogenic Shock: ECMO Supported TAVR

Presenter: Mark Bieniarz

March 21, 2023

Presentation THT 2023

Assessing RV Function in Cardiogenic Shock: When to Pull the Trigger on MCS

Presenter: Arthur Reshad Garan

March 21, 2023

Presentation THT 2023

Application of the Cardiogenic Shock Working Group (CSWG)-defined Society for Cardiovascular Angiography and Interventions (SCAI) staging of cardiogenic shock (CS) to the Medical Information Mart for Intensive Care (MIMIC)-IV Database

Presenter: Kevin John

March 21, 2023

Presentation THT 2023

Outcomes of Patients with Sarcoidosis and Concomitant Cardiogenic Shock

Presenter: Rohan Umrani

March 21, 2023

Presentation THT 2023

The Cardiogenic Shock Team in Acute Myocardial Infarction Cardiogenic Shock: A Crew Resource Management Approach

Presenter: Mark Jacobs

March 21, 2023

Presentation THT 2023

Age Differences in the In-Hospital Outcomes of Cardiogenic Shock in the United States

Presenter: Siddharth Agarwal

March 21, 2023

Presentation THT 2023

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

Presenter: Graham Nichol

March 20, 2023

Presentation THT 2023

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

Presenter: Navin Kapur

March 20, 2023

Presentation THT 2023

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Presenter: Gregg Stone

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Mauro Moscucci

March 20, 2023

Presentation THT 2023

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

Presenter: Song Li

March 20, 2023

Presentation THT 2023

Biomarkers and Risk Stratification for Cardiogenic Shock

Presenter: Ajar Kochar

March 20, 2023

Presentation THT 2023

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

Presenter: David Baran

March 20, 2023

Presentation THT 2023

Treating the Right Ventricle in Cardiogenic Shock: the Next Frontier in Improving Outcomes

Presenter: Michele Esposito

March 20, 2023

Presentation THT 2023

Intra-Aortic Balloon Counterpulsation: "I'll Be Back"

Presenter: Sandeep Nathan

March 20, 2023

Presentation THT 2023

Trans-Valvular LV Support: a Glimpse Into the Future

Presenter: Colin Hirst

March 20, 2023

Presentation THT 2023

What Do We Really Know About ECMO in Cardiogenic Shock?

Presenter: Navin Kapur

March 20, 2023

Presentation THT 2023

When To Transition From Medical to Device-Based Therapy

Presenter: Shelley Hall

March 20, 2023

Advertisement

Cardiogenic Shock With MCS and Review of Shock Algorithm

Aortic Stenosis TAVR With Annular Rupture/ Tamponade

Cardiogenic Shock: ECMO Supported TAVR

Assessing RV Function in Cardiogenic Shock: When to Pull the Trigger on MCS

Application of the Cardiogenic Shock Working Group (CSWG)-defined Society for Cardiovascular Angiography and Interventions (SCAI) staging of cardiogenic shock (CS) to the Medical Information Mart for Intensive Care (MIMIC)-IV Database

Outcomes of Patients with Sarcoidosis and Concomitant Cardiogenic Shock

The Cardiogenic Shock Team in Acute Myocardial Infarction Cardiogenic Shock: A Crew Resource Management Approach

Age Differences in the In-Hospital Outcomes of Cardiogenic Shock in the United States

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

FDA Introduction

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

Biomarkers and Risk Stratification for Cardiogenic Shock

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

Treating the Right Ventricle in Cardiogenic Shock: the Next Frontier in Improving Outcomes

Intra-Aortic Balloon Counterpulsation: "I'll Be Back"

Trans-Valvular LV Support: a Glimpse Into the Future

What Do We Really Know About ECMO in Cardiogenic Shock?

When To Transition From Medical to Device-Based Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content